Trial Profile
Single agent chemotherapy with weekly docetaxel vs combination chemotherapy in second-line treatment of advanced non small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Capecitabine; Gemcitabine; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DISTAL-2
- 01 Feb 2009 Primary endpoint 'overall Survival duration' has not been met.
- 01 Feb 2009 Results reported in Lung Cancer.
- 26 May 2008 Results presented at ASCO 2008.